NCT01833520View on ClinicalTrials.gov

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 16, 2013

Primary Completion Date

April 8, 2020

Study Completion Date

April 8, 2020

Conditions

Sarcoma

Interventions

DRUG

Ra-223 Dichloride

"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston